Publication | Open Access

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Phase IiAdvanced Ovarian CancerMedicineCancer ManagementGynecologyCancer TreatmentOncologyRadiation OncologyWeeks Dose SchedulesGynecology OncologyOvarian Cancer